Abstract 2348 Investigating the anti-cancer effects of Spinosyn A in argininosuccinate synthetase 1 low-expressing renal cell carcinoma cells

Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer in adults, instituting a need for new treatment methods.Variants of RCC characterized by low argininosuccinate synthetase 1 (ASS1) expression are associated with poor prognosis, yet the tumor-suppressive mechanisms of ASS1 remain underexplored.This study explores the effects of Spinosyn A (SPA), a compound naturally derived from the fermentation of soil bacterium S. spinosa, in RCC.SPA has demonstrated anti-cancer properties, particularly affecting signaling pathways responsible for cell cycle regulation and proliferation.We focus on two renal cancer cell lines, UO-31 and SN12C, which exhibit low ASS1 expression and harbor distinct oncogenic mutations to elucidate SPA's impact on tumorigenic processes.We plan to utilize flow cytometry and RNA sequencing to explore the potential effects of SPA on proliferation, migration, and apoptosis.Additionally, we aim to investigate SPA-induced alterations in cell morphology and migration dynamics using real-time holographic imaging microscopy.By integrating these methodologies, our research aims to uncover the molecular mechanisms driving RCC progression and evaluate SPA's potential as a novel therapeutic agent.These findings may provide critical insights into ASS1's role as a tumor suppressor and inform future development of SPA-based cancer therapies.